"Androgen Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which inhibit or antagonize the biosynthesis or actions of androgens.
Descriptor ID |
D000726
|
MeSH Number(s) |
D06.347.065 D27.505.696.399.450.065
|
Concept/Terms |
Anti-Androgen Effect- Anti-Androgen Effect
- Anti Androgen Effect
- Effect, Anti-Androgen
- Antiandrogen Effect
- Effect, Antiandrogen
- Antiandrogen Effects
- Effects, Antiandrogen
- Anti-Androgen Effects
- Anti Androgen Effects
- Effects, Anti-Androgen
|
Below are MeSH descriptors whose meaning is more general than "Androgen Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Androgen Antagonists".
This graph shows the total number of publications written about "Androgen Antagonists" by people in this website by year, and whether "Androgen Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 1 | 2 |
1995 | 1 | 0 | 1 |
1996 | 2 | 2 | 4 |
1997 | 0 | 2 | 2 |
1998 | 1 | 1 | 2 |
1999 | 0 | 4 | 4 |
2000 | 0 | 3 | 3 |
2001 | 0 | 3 | 3 |
2002 | 1 | 0 | 1 |
2003 | 1 | 4 | 5 |
2004 | 3 | 2 | 5 |
2005 | 0 | 6 | 6 |
2006 | 6 | 1 | 7 |
2007 | 7 | 3 | 10 |
2008 | 4 | 3 | 7 |
2009 | 3 | 4 | 7 |
2010 | 7 | 8 | 15 |
2011 | 6 | 7 | 13 |
2012 | 5 | 7 | 12 |
2013 | 13 | 5 | 18 |
2014 | 5 | 2 | 7 |
2015 | 9 | 2 | 11 |
2016 | 6 | 7 | 13 |
2017 | 9 | 2 | 11 |
2018 | 4 | 4 | 8 |
2019 | 5 | 0 | 5 |
2020 | 8 | 5 | 13 |
2021 | 7 | 8 | 15 |
2022 | 2 | 10 | 12 |
2023 | 1 | 11 | 12 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Androgen Antagonists" by people in Profiles.
-
Functional Outcomes After Localized Prostate Cancer Treatment. JAMA. 2024 01 23; 331(4):302-317.
-
Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer. Curr Treat Options Oncol. 2024 Jan; 25(1):66-83.
-
Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment. Nat Cell Biol. 2023 Dec; 25(12):1821-1832.
-
MRI and PSMA PET/CT of Biochemical Recurrence of Prostate Cancer. Radiographics. 2023 Dec; 43(12):e230112.
-
Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients' Real-World Insights for Optimizing Outcomes. Adv Ther. 2024 Feb; 41(2):476-491.
-
Metastases-Targeting Radiotherapy and ADT-Reply. JAMA Oncol. 2023 Nov 01; 9(11):1587-1588.
-
A novel GRK3-HDAC2 regulatory pathway is a key direct link between neuroendocrine differentiation and angiogenesis in prostate cancer progression. Cancer Lett. 2023 09 01; 571:216333.
-
A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer. J Exp Clin Cancer Res. 2023 Jul 29; 42(1):187.
-
The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, Access?to Imaging and Treatment of Metastatic Prostate Cancer. Clin Oncol (R Coll Radiol). 2023 10; 35(10):e628-e635.
-
TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2023 05 16; 120(20):e2218229120.